AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00295854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible patients received placebo
Study NCT00290121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Study NCT03540810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: The patients will additionally receive this drug with their usual treatment to evaluate its efficiency to prevent new thrombotic events in primary antiphospholipid syndrome patients
Study NCT03540810 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients will receive placebo with their usual treatment
Study NCT01400282 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: High frequency spinal cord stimulation
Study NCT02958657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Supervised exercise training program that includes two workouts per week for three months at a rehabilitation unit.
Study NCT02577354 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReActiv8 Implantable Stimulation System (Patient Appropriate Stimulation)
Description: ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level, and participants instructed to deliver stimulation in two 30-minute sessions per day.
Study NCT02577354 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReActiv8 Implantable Stimulation System (Low Stimulation)
Description: ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.
Study NCT03756753 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Results available to provider
Description: Results of point of care testing are given to provider
Study NCT04459663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab injection combine with Axitinib
Description: The patients in the group will be infused intravenously with fixed dose of 240mg JS001 on the first day of each cycle. Oral Axitinib 5mg bid (recommended interval of about 12 hours) was given daily from the second day of the initial cycle
Study NCT01711762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0973
Description: Single oral dose of \[14C\]-GDC-0973
Study NCT02097979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Glaucoma Educational Intervention
Study NCT03893721 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: arsenic exposure
Description: analysis of hair samples for Arsenic using Agilent graphite tube atomizer 120
Study NCT01701986 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Undergo allogeneic BMT
Study NCT01701986 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic BMT or PBSCT
Study NCT01701986 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Given IV
Study NCT01701986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV
Study NCT01701986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Given IV
Study NCT01701986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT01701986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV then PO
Study NCT01701986 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic PBSCT
Study NCT01701986 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01701986 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT01701986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV then PO
Study NCT03350334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Peri-operative Duloxetine administration
Study NCT03350334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo administration
Study NCT00654719 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NutriDrink
Description: Nutritional supplementation that contains 600 kcal/day: protein content 20 g, carbohydrates 72 g, fat 26 g
Study NCT00654719 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nutritional supplementation containing only 12 kcal/day
Study NCT00533104 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BM-MNC preparation
Description: For autologous bone marrow - mononuclear cells preparation, 500ml of bone marrow are collected under general anaesthesia; mononuclear cells are separated using a blood-cells separator (COBE SPECTRA, GAMBRO BCT) and concentrated to produce a final volume of 40ml.~Cells are implanted 1 to 3 hours after preparation by multiple intramuscular injections into the gastrocnemius of the ischemic leg.(30 injection sites, 1 to 1.5 cm deep, spaced 1 cm apart,1 ml per injection).
Study NCT00533104 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PB-MNC preparation
Description: Peripheral blood - mononuclear cells are collected through cytapheresis with the same blood-cells separator which is adjusted to obtain a 40 mL cell product. No previous mobilization with hematopoïetic growth-factor is administered.~Cells are implanted 1 to 3 hours after preparation by multiple intramuscular injections into the gastrocnemius of the ischemic leg.(30 injection sites, 1 to 1.5 cm deep, spaced 1 cm apart,1 ml per injection).
Study NCT02837640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa-carbidopa
Description: sinemet 200/50 1/2 tablet b.i.d. for 2 days and then t.i.d for 6 months
Study NCT03255824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine and Midazolam
Description: Administration of Dexmedetomidine and Midazolam for sedation during third molar surgery.
Study NCT03255824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol, Midazolam, and Fentanyl
Description: Administration of Propofol, Midazolam, and Fentanyl for sedation during third molar surgery.
Study NCT03924479 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PowerBreathe (Breathing muscle training)
Description: The breathing muscle breathing training will consist of using the PowerBreathe training for 8 weeks. The PowerBreathe is an inspiratory pressure threshold trainer.The valve blocks the airflow until the threshold pressure is achieved by breathing in forcefully into the device.
Study NCT03924479 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PowerBreathe (Breathing muscle training)
Description: The breathing muscle breathing training will consist of using the PowerBreathe training for 8 weeks. The PowerBreathe is an inspiratory pressure threshold trainer.The valve blocks the airflow until the threshold pressure is achieved by breathing in forcefully into the device.
Study NCT00198484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitrase
Study NCT00785291 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Given IV
Study NCT00785291 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT00785291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Given IV
Study NCT01125241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: wuling capsule
Description: orally, three tablets each time,three times a day
Study NCT01125241 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo of wuling capsule
Description: orally, three tablets each time and three times a day
Study NCT04317573 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Personalised card
Description: An individualised card containing the patient's eye drops regime was printed for the patient after his/consult with the physician to be brought home.
Study NCT04180852 — intervention group
Intervention type: OTHER
Intervention: Functional tests without clinical consequence for the patients therapy
Description: Battery of tests, which measure the patients functional outcomes regarding their muscle mass, their muscle strength, fat mass, physical function, neuropsychological function and quality of life.
Study NCT03424902 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cardiac computed tomography and cardiac catheterization
Description: assesment of certain predictors with CT and fluroscopy for paravalvular leakage
Study NCT01909193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Description: Attention training via 8 weekly repeated trials of a dot-probe task intended to direct attention away from threat stimuli.
Study NCT01909193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy
Description: CBT will consist of 16-20 weekly individual treatment sessions aimed to reduce symptoms via cognitive and behavioral interventions
Study NCT03491046 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET scan
Description: low dose fluorodeoxyglucose (FDG) PET research scan with CEST sequence
Study NCT03491046 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: standard of care MRI
Study NCT01942486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Coating
Study NCT03058250 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transesophageal echocardiography
Study NCT04167098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRP injection
Description: 0.5 ml Platelet-rich Plasma around A1 tendon sheath
Study NCT04167098 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection
Description: 0.5 ml methylprednisolone around A1 tendon sheath
Study NCT04167098 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: 0.5 ml 0.9% saline around A1 tendon sheath
Study NCT01132248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefloquine
Description: 15mg/kg mefloquine per dose Women receive two doses: One after the first trimester of pregnancy and the second at least one month after the first dose
Study NCT01132248 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S/P
Description: sulfadoxine-pyrimethamine IPTp will be administered following current WHO recommendations
Study NCT02318355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: normal saline
Description: Crystalloid intravenous solution
Study NCT02318355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lactated ringers
Description: Crystalloid intravenous solution
Study NCT01888445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roxadustat
Description: oral
Study NCT00785291 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00785291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00785291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV
Study NCT00785291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT00785291 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00785291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03139422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid 500 MG
Description: oral tablets
Study NCT03139422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Dobesilate
Description: oral tablets
Study NCT03313518 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: 15 patients received real anodal tDCS for 20 minutes daily for 10 consecutive days.
Study NCT03313518 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: 15 patients received sham anodal tDCS for 20 minutes daily for 10 consecutive days.
Study NCT04960605 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dental implants
Description: Treatment of the toothless regions with dental implants
Study NCT02987075 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Compacting embryo transferring
Description: transfer of 2 utilizable compacting embryos
Study NCT02987075 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Non- compacting embryo transferring
Description: transfer of 2 utilizable non-compacting embryos have 7-9 cells with under 20% fragmentation.
Study NCT05519280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the Biopsychosocial-Spiritual Group Intervention
Description: The Experimental group received 8 sessions of weekly BPS-S group therapy for 80 minutes each.
Study NCT02057874 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3 Tesla Magnetic Resonance Imaging
Description: 3T MRI consists of a series of radiofrequency (RF) pulse sequences optimized for acquiring CEST-, MT-, DW-, and DCE-MRI data in one seamless imaging examination. For DCE, MR contrast agent will be intravenously administered.
Study NCT02057874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnevist® (Intravenous (IV) administration of MRI contrast agent)
Description: For the acquisition of DCE-MR data, the FDA-approved contrast agent Magnevist® (gadopentetate dimeglumine, 0.1 mmol/kg) will be delivered intravenously by the MR technologist at a rate of 2 mL/sec (followed by a saline flush) via a power injector after the acquisition of a set of baseline dynamic scans. The entire sequence lasts approximately 8 minutes.
Study NCT01866943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic Acid 1.5 g (100 mg/mL)in 100cc normal saline is applied topically to the wound for 5 minutes time then suctioned and the skin closed. The control group receives just normal saline and no drug.
Study NCT01866943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Solution
Study NCT01568099 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFFITOPE® PD01A
Description: s.c. injection
Study NCT01568099 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Untreated control
Study NCT02520167 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary and Lifestyle Counseling
Description: Dietary and lifestyle education; Peer group support.
Study NCT00752843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone + fluvastatin
Description: Subjects will receive a single oral dose of 40 mg PO of fluvastatin on three occasions: alone (Day 1), at the same time as a single dose of CORLUX 1200 mg (Day 8) and during concomitant administration of CORLUX 1200 mg/day (CORLUX on Days 8-14, fluvastatin on Day 14).
Study NCT02943850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem cell (HPC) implantation
Description: All patients will received unilateral lumbar spinal cord injections of CNS10-NPC-GDNF cells.
Study NCT02943850 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stereotactic surgical device
Description: A newly developed stereotactic frame is being evaluated as a part of this trial
Study NCT02037048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT02037048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: Given IV
Study NCT02037048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT02037048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Description: Given IV
Study NCT02037048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT02037048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: Given IV
Study NCT02037048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo therapeutic conventional surgery
Study NCT02037048 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Undergo therapeutic conventional surgery
Study NCT02037048 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study NCT02037048 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Undergo radiation therapy
Study NCT02037048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT02037048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00892502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth tablets
Description: 1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy
Study NCT00892502 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: 1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy
Study NCT01410058 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Moringa oleifera
Description: leaf powder, 1.85g once daily, hard gelatin capsules
Study NCT01410058 — intervention group
Intervention type: DRUG
Intervention: Efavirenz 600mg
Description: Efavirenz 600mg based regimen
Study NCT01410058 — intervention group
Intervention type: DRUG
Intervention: Nevirapine 200Mg Oral Tablet
Description: Nevirapine 200mg based regimen
Study NCT00389883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of two anesthetics protocol
Description: Comparison of two anesthetics protocol
Study NCT00389883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of two anesthetics protocol
Description: Comparison of two anesthetics protocol
Study NCT03910413 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Duel Energy CT
Description: Enrolled subjects will complete a dual energy ct for evaluation of esophageal varices
Study NCT02792361 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Suction Drain
Description: The intervention of the experimental group will be a standard suction drain placed at the surgical site following a Pterional Craniotomy.
Study NCT02647606 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MILS
Description: MILS(Manual in-line stabilization) will be applied during intubation. With MILS, different kinds of laryngoscope will be evaluated in a simulated difficult airway.
Study NCT02647606 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGrath videolaryngoscope
Description: McGrath videolaryngoscope will be used for intubation
Study NCT02647606 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pentax AWS videolaryngoscope
Description: Pentax AWS videolaryngoscope will be used for intubation
Study NCT02647606 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Description: Macintosh laryngoscope will be used for intubation
Study NCT04382105 — intervention group
Intervention type: OTHER
Intervention: Observation of salivary IL-6 levels
Description: Observation of salivary IL-6 levels and correlation of salivary IL-6 levels with periodontal disease
Study NCT04573621 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic drain
Description: A pelvic drain is placed
Study NCT04573621 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No pelvic drain is placed
Description: A pelvic drain is not placed
Study NCT04424862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone, ciclosporin and mycophenolate mofetil
Description: Multitarget Therapy
Study NCT04424862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ponticelli Regimen
Description: Month 1: i.v. methylprednisolone (0.5 g) daily for three doses, then oral prednison (0.5 mg/kg/d, maximum dose 30mg/d) for 27 days Month 2: Oral cyclophosphamide (2.0 mg/kg/d, maximum dose 100mg/d) for 30 days Month 3: Repeat Month 1 Month 4: Repeat Month 2 Month 5: Repeat Month 1 Month 6: Repeat Month 2
Study NCT00289887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: losartan +/- HCTZ
Description: Placebo to losartan once daily for 4 weeks in run-in period. Then, losartan 50 mg for 4 weeks, then titrate to losartan 100 mg at Week 4, then titrate to losartan 100 mg + hydrochlorothiazide (HCTZ) 12.5 mg at Week 8, and finally titrate to losartan 100 mg + HCTZ 25 mg at Week 12. Duration of treatment is approximately 16 weeks.